MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02528nam a22003017a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
170428s20172017 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
1774-024X |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
28262623 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Second-generation Magnesium Scaffold Magmaris, Device Design, and Preclinical Evaluation in a Porcine Coronary Artery Model. |
| 251 ## - Source |
|---|
| Source |
Eurointervention. , 2017 Mar 07 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
EuroIntervention. , 2017 Mar 07 |
| 253 ## - Journal Name |
|---|
| Journal name |
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2017 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2017 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2017-05-06 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AIMS: The second-generation drug-eluting absorbable magnesium scaffold Magmaris, recently introduced for treatment of obstructive coronary atherosclerotic lesions, suggests a good safety profile, but preclinical assessment is important for predicting clinical performance. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: Preclinical results suggest Magmaris has a favourable safety profile with advanced healing relative to benchmark, low acute thrombogenicity, and absence of excessive lumen loss up to 2 years and support clinical application of Magmaris for human use. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS AND RESULTS: Ninety Magmaris scaffolds were implanted into non-diseased porcine and rabbit models. A bioresorbable vascular scaffold (Absorb) and the permanent drugeluting stent (Xience Xpedition) served as controls. Scanning electron microscopy showed increased endothelialisation and decreased thrombus formation at 3 and 28 days in the Magmaris group compared with the Absorb group. In the Xience group, inflammation exceeded the level in the Magmaris group at 365 and 720 days. Neointimal growth was greater in the Magmaris group than in the Xience group. Late lumen loss decreased over time in both groups. Optical coherence tomography (OCT) showed stable luminal dimensions in both the Magmaris and Xience groups. Pharmacokinetic studies demonstrated a retarded elution profile in the Magmaris group with 69.4 % of sirolimus released at 90 days. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Waksman, Ron |
| 790 ## - Authors |
|---|
| All authors |
Haude M, Joner M, Lapointe-Corriveau C, Leclerc G, Pritsch M, Waksman R, Wittchow E, Zumstein P |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.4244/EIJ-D-16-00915">https://dx.doi.org/10.4244/EIJ-D-16-00915</a> |
| Public note |
https://dx.doi.org/10.4244/EIJ-D-16-00915 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
